The stock of Applied Therapeutics Inc (APLT) has gone down by -13.90% for the week, with a -6.52% drop in the past month and a -44.72% drop in the past quarter. The volatility ratio for the week is 9.07%, and the volatility levels for the past 30 days are 11.52% for APLT. The simple moving average for the last 20 days is -13.37% for APLT stock, with a simple moving average of -89.53% for the last 200 days.
Is It Worth Investing in Applied Therapeutics Inc (NASDAQ: APLT) Right Now?
The stock has a 36-month beta value of 1.99. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for APLT is 91.25M, and at present, short sellers hold a 19.94% of that float. On April 02, 2025, the average trading volume of APLT was 3.51M shares.
APLT) stock’s latest price update
Applied Therapeutics Inc (NASDAQ: APLT) has seen a decline in its stock price by -2.08 in relation to its previous close of 0.46. However, the company has experienced a -13.90% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-31 that NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company’s Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25.
Analysts’ Opinion of APLT
UBS, on the other hand, stated in their research note that they expect to see APLT reach a price target of $2, previously predicting the price at $13. The rating they have provided for APLT stocks is “Neutral” according to the report published on December 02nd, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to APLT, setting the target price at $4 in the report published on November 29th of the previous year.
APLT Trading at -17.78% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.76% of loss for the given period.
Volatility was left at 11.52%, however, over the last 30 days, the volatility rate increased by 9.07%, as shares sank -14.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.24% lower at present.
During the last 5 trading sessions, APLT fell by -16.42%, which changed the moving average for the period of 200-days by -91.68% in comparison to the 20-day moving average, which settled at $0.5195. In addition, Applied Therapeutics Inc saw -47.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Perfetti Riccardo, who sale 10,366 shares at the price of $0.44 back on Mar 04 ’25. After this action, Perfetti Riccardo now owns 890,409 shares of Applied Therapeutics Inc, valued at $4,561 using the latest closing price.
Funtleyder Leslie D., the insider of Applied Therapeutics Inc, sale 14,502 shares at $0.44 during a trade that took place back on Mar 04 ’25, which means that Funtleyder Leslie D. is holding 390,459 shares at $6,381 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- 437.36 for the present operating margin
- 3.79 for the gross margin
The net margin for Applied Therapeutics Inc stands at 887.73. The total capital return value is set at -12.14.
Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -41.52. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is -127.99.
Currently, EBITDA for the company is -64.53 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 210.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.
Conclusion
To sum up, Applied Therapeutics Inc (APLT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
